This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Hapvida can participate in Brazilian review of Gerdau-Unimed deal

( December 8, 2023, 15:06 GMT | Official Statement) -- MLex Summary: Healthcare plan operator Hapvida can participate as an interested third party in the review of a deal involving steelmaker Gerdau Açominas and Unimed, according to a statement. However, the Superintendence of the Administrative Council for Economic Defense, or CADE, said it can overturn its decision if Hapvida doesn't provide the agency with pertinent information to prove its allegations about the deal. The transaction involves a planned investment by healthcare plan operator Unimed in Fundação Ouro Branco, which provides health services and is controlled by Gerdau. As an interested third party, Hapvida can assist CADE in its investigation.CADE statement and decision follow in Portuguese....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections